Who is in charge of assessing therapeutic drug monitoring? The case of imatinib.
Division of Clinical Pharmacology and Toxicology, Department of Medicine, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne 1011, Switzerland. thierry.buclin@chuv.ch
Thierry
T
Buclin
Nicolas
N
Widmer
Jerome
J
Biollaz
Laurent A
LA
Decosterd
D000970:Antineoplastic Agents / Q000097:blood*; D001549:Benzamides; D004345:Drug Industry; D016903:Drug Monitoring; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D010879:Piperazines / Q000097:blood*; D047428:Protein Kinase Inhibitors / Q000097:blood*; D011743:Pyrimidines / Q000097:blood*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate